Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF

Sudden death is a leading cause of mortality in heart failure with reduced ejection fraction (HFrEF). In PARADIGM‐HF, sacubitril/valsartan reduced the incidence of sudden death. The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.

[1]  A. Brandes,et al.  Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  S. Fisher,et al.  Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. , 1998, Journal of the American College of Cardiology.

[3]  R. H. Mohamed,et al.  Angiotensin receptor-neprilysin inhibitior)thiorphan/irbesartan( decreased ischemic-reperfusion induced ventricular arrhythmias in rat; in vivo study. , 2020, European journal of pharmacology.

[4]  S. Solomon,et al.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, JAMA.

[5]  B. Mariottoni,et al.  Declining Risk of Sudden Death in Heart Failure. , 2017, The New England journal of medicine.

[6]  Akshay S. Desai,et al.  Serum potassium in the PARADIGM‐HF trial , 2020, European journal of heart failure.

[7]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[8]  Akshay S. Desai,et al.  Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2019, JAMA.

[9]  M. Henzlova,et al.  Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators. , 1995, The American journal of cardiology.

[10]  John L Sapp,et al.  Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. , 2016, The New England journal of medicine.

[11]  E. Schiffrin,et al.  Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats , 2005, Journal of hypertension.

[12]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[13]  Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization , 2016, European Journal of Clinical Pharmacology.

[14]  J. McMurray,et al.  Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials , 2018, Clinical Research in Cardiology.

[15]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[16]  P. Ponikowski,et al.  Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF , 2021, European heart journal.

[17]  S. Yun,et al.  Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study , 2019, Circulation.

[18]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[19]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[20]  A. Bayés‐Genís,et al.  Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug? , 2018, Circulation.

[21]  J. Almendral,et al.  Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. , 2017, Heart rhythm.

[22]  B. Massie,et al.  Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. , 2000, Circulation.

[23]  G. Hasenfuss,et al.  Sacubitrilat reduces pro‐arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end‐stage heart failure , 2020, ESC heart failure.

[24]  S. Solomon,et al.  Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. , 2019, Journal of the American College of Cardiology.

[25]  B. Burnand,et al.  Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews , 2018, BMJ Open.

[26]  J. Vercammen,et al.  Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction , 2019, Clinical Research in Cardiology.

[27]  Akshay S. Desai,et al.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.

[28]  Anindita Das,et al.  Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits. , 2018, Journal of the American College of Cardiology.

[29]  P. Golino,et al.  The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator , 2020, Journal of clinical medicine.

[30]  H. Kennedy,et al.  Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. , 1999, American heart journal.

[31]  Shien‐Fong Lin,et al.  Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmias Inducibility in a Rabbit Myocardial Infarction Model. , 2020, Journal of cardiac failure.

[32]  Akshay S. Desai,et al.  Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. , 2020, JACC. Heart failure.

[33]  M. Packer.  What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? , 2019, European heart journal.

[34]  Shien‐Fong Lin,et al.  Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy , 2020, ESC heart failure.

[35]  Yong Peng,et al.  The Effect of Aldosterone Antagonists for Ventricular Arrhythmia: A Meta‐Analysis , 2010, Clinical cardiology.

[36]  Fa‐Po Chung,et al.  Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril/valsartan treatment. , 2020, European heart journal. Cardiovascular pharmacotherapy.